Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EPS (Weighted Average and Diluted): 2016-2017

  • UroGen Pharma's EPS (Weighted Average and Diluted) fell 52.56% to $0.74 in Q4 2017 from the same period last year, while for Dec 2017 it was $4.53, marking a year-over-year change of. This contributed to the annual value of $2.14 for FY2017, which is 12.04% up from last year.
  • Latest data reveals that UroGen Pharma reported EPS (Weighted Average and Diluted) of $0.74 as of Q4 2017, which was up 9.88% from $0.67 recorded in Q2 2017.
  • Over the past 5 years, UroGen Pharma's EPS (Weighted Average and Diluted) peaked at $1.56 during Q2 2016, and registered a low of $0.67 during Q2 2017.
  • Its 2-year average for EPS (Weighted Average and Diluted) is $1.13, with a median of $1.15 in 2017.
  • Data for UroGen Pharma's EPS (Weighted Average and Diluted) shows a maximum YoY plummeted of 56.84% (in 2017) over the last 5 years.
  • UroGen Pharma's EPS (Weighted Average and Diluted) (Quarterly) stood at $1.56 in 2016, then plummeted by 52.56% to $0.74 in 2017.
  • Its last three reported values are $0.74 in Q4 2017, $0.67 for Q2 2017, and $1.56 during Q4 2016.